Stifel Positive on NervGen's Outlook

MT NewswiresDec 24, 2024 13:02 ET

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291

MT NewswiresSep 30, 2024 10:56 ET

NervGen Pharma to Advance New Drug Candidate Into Preclinical Proof-of-Concept Stage

MT NewswiresJun 25, 2024 13:18 ET

NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus

Dow JonesMay 1, 2024 12:01 ET

NervGen Pharma Corp: MDA EN

SEDARApr 17, 2024 08:31 ET · Announcements

NervGen Pharma Corp: AUDITED ANNUAL FINANCIAL STATEMENTS EN

SEDARApr 17, 2024 08:30 ET · Announcements